Meeting
2019 ASCO Annual Meeting
Venous thromboembolism (VTE) in patients with ALK-rearranged non-small cell lung cancer (ALK-LC): A population-based cohort.
Authors
Alona Zer
Sarcoma Unit, Davidoff Cancer Institute, Rabin Medical Center, affiliated to the Sackler Faculty of Medicine, Petach Tiqwa, Israel
Alona Zer , Lilach Joseph , Erez Battat , Tzippy Shochat , Avi Leader , Daniel A. Goldstein , Ariel Hammerman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Quality Improvement
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6608)
DOI
10.1200/JCO.2019.37.15_suppl.6608
Abstract #
6608
Poster Bd #
299
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
First Author: Sun Min Lim
Poster
2023 ASCO Quality Care Symposium
Impact of integrating standardized venous thromboembolism (VTE) prophylaxis orders for patients with multiple myeloma into an electronic health record (EHR).
First Author: Andrea Dickens
Poster
2023 ASCO Annual Meeting
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
First Author: Nicolas Girard
Poster
2017 ASCO Quality Care Symposium
Post-discharge venous thromboembolism prophylaxis for surgical oncology patients.
First Author: Ashlie Nadler